Clinical trial
Phase I Combination w/ Epirubicin
NCT00322374 · R-Pharm, Industry · Completed
Key facts
| NCT number | NCT00322374 |
|---|---|
| Title | Phase I Combination w/ Epirubicin |
| Official title | A Phase I Study of Ixabepilone in Combination With Epirubicin in Patients With Metastatic Breast Cancer |
| Lead sponsor | R-Pharm, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Ixabepilone, Epirubicin |
| Enrollment | 42 |
| Start date | Aug 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | May 5, 2006 |
| Last update posted | Mar 10, 2016 |
| Countries | France, Italy |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: